NCT00147784View on ClinicalTrials.gov

HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

January 31, 2008

Conditions
Opiate DependenceHepatitis
Interventions
DRUG

Ribavirin

800 mg pr. os daily, 400 mg morning and 400 mg evening (200 mg/tbl.) for 14 weeks

DRUG

Pegylated Interferon

180 mikrogram in 0,5 ml solution s.c. once a week for 14 weeks

Trial Locations (2)

4604

Soerlandet Hospital HF, Kristiansand

N-4604

Addiction Unit, Sorlandet Hospital, Kristiansand

All Listed Sponsors
lead

Sorlandet Hospital HF

OTHER_GOV

NCT00147784 - HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group. | Biotech Hunter | Biotech Hunter